What is XYWAV
XYWAV is the first and only low‑sodium* oxybate treatment for cataplexy and/or excessive daytime sleepiness (EDS) in narcolepsy
*XYWAV contains 131 mg of sodium at the maximum recommended nightly dose.
XYWAV, taken at night, is thought to work during sleep to help improve 2 common symptoms of narcolepsy during the day†
XYWAV is the first and only low-sodium oxybate approved by the FDA for treating cataplexy and/or EDS in people ages 7 years and older with narcolepsy.
XYWAV can be taken in addition to daytime medications like stimulants. Be sure to talk to your doctor about any medications you are taking or plan to take.
- †The exact way XYWAV works for the treatment of cataplexy and EDS in patients with narcolepsy is unknown.
Reasons to talk to your doctor about XYWAV today
XYWAV is thought to work during sleep to help improve symptoms of cataplexy and EDS during the day.‡
- ‡The exact way XYWAV works for the treatment of cataplexy and EDS in patients with narcolepsy is unknown.
XYWAV is a low-sodium oxybate treatment with 92% less sodium than high-sodium oxybates. That's as much as ~1509 mg less sodium per night.§
- §At the maximum recommended nightly dose.
Choosing XYWAV over high-sodium oxybates, means you can help treat your symptoms of cataplexy and/or EDS in narcolepsy while also reducing your sodium intake, a modifiable risk factor for cardiovascular disease.
XYWAV is the first and only lower-sodium‖ oxybate approved by the FDA for treating cataplexy and/or excessive daytime sleepiness (EDS) in people ages 7 years and older with narcolepsy.
‖Compared to XYREM® (sodium oxybate) oral solution and LUMRYZ™ (sodium oxybate) for extended-release oral suspension. XYWAV has never been directly compared to XYREM or LUMRYZ in a clinical study.Get the Discussion Guide
How was XYWAV studied?
The efficacy and safety of XYWAV was studied in 201 adults with narcolepsy with cataplexy who had at least 14 cataplexy attacks in a typical 2‑week period before they took any treatment.¶#
All people in the clinical study started treatment with XYWAV.
The majority of participants (59%) continued taking their stimulant or wake‑promoting agent along with XYWAV.
XYWAV was adjusted to a stable dose (the dose that worked best for each person). Then they were randomly assigned to:
- Continue treatment with XYWAVOR
- Stop taking XYWAV for 2 weeks. These people were switched to a placebo, a treatment that is inactive. This was to see if there was a difference in their symptoms
- ¶Study included people aged 18-70.
- #Not everyone completed each part of the trial. Of the 201 patients, 134 were included in the 2-week period that measured how well XYWAV worked.
Unlike other medications taken during the day, XYWAV is taken at night
Get valuable information about XYWAV from experts in sleep medicine
Learn about narcolepsy and also XYWAV, which may help treat cataplexy and/or EDS in people with narcolepsy. Plus, learn about the sodium content of XYWAV and why that matters for people with narcolepsy.Intro to Xywav